A recent report revealed an essential role for nonproteolytic Ub pathway in Twist activation and Twist-mediated EMT and CSC acquisition [121], suggesting that targeting the controlling E3 ligases for K63-linked Ub of EMT-TFs can be a potential approach for development of EMT/CSC-based new cancer therapeutics. The gene discussed is TWIST1; the disease is cancer.